Sandesh Mahatme

CIK: 0001511034

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (20.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

CRSP

CRISPR Therapeutics AG

Director

VOR

Vor Biopharma Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

CRSP
CRISPR Therapeutics AG
Jun 5, 2026
Award(A)
Stock Option (Right to Buy)
Direct
13K shares-
VOR
Vor Biopharma Inc.
Dec 5, 2025
Disposition(D)
Direct
694.1K shares-
VOR
Vor Biopharma Inc.
Dec 5, 2025
Award(A)
Employee Stock Option (right to buy)
Direct
1.4M shares-
VOR
Vor Biopharma Inc.
Jul 9, 2025
Award(A)
Direct
13.9M shares-
CRSP
CRISPR Therapeutics AG
Jun 5, 2025
Award(A)
Stock Option (Right to Buy)
Direct
13K shares-

		Type	Shares	Price		Ownership
Jun 5, 2026	CRSP CRISPR Therapeutics AG	Award(A) Stock Option (Right to Buy)	13,000	-	-	Direct
Dec 5, 2025	VOR Vor Biopharma Inc.	Disposition(D)	694,137	-	-	Direct
Dec 5, 2025	VOR Vor Biopharma Inc.	Award(A) Employee Stock Option (right to buy)	1,388,274	-	-	Direct
Jul 9, 2025	VOR Vor Biopharma Inc.	Award(A)	13,882,750	-	-	Direct
Jun 5, 2025	CRSP CRISPR Therapeutics AG	Award(A) Stock Option (Right to Buy)	13,000	-	-	Direct

1-5 of 5 transactions

About Mahatme Sandesh

Mahatme Sandesh (SEC CIK 0001511034) files insider reports with the SEC as Director of CRISPR Therapeutics AG (CRSP) and CFO of Vor Biopharma Inc. (VOR).

Signal8 holds 5 ownership filings by Mahatme Sandesh (1 Form 3, 4 Form 4), filed between Jun 6, 2025 and Jun 9, 2026. Those filings report 5 transactions, from Jun 5, 2025 to Jun 5, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Mahatme Sandesh's filings is in BOSTON, MA.

Recent filings by Mahatme Sandesh

Jun 5, 2026: Grant or award of CRSP derivative securities (Form 4, code A).
Dec 5, 2025: Disposition to issuer transaction of VOR shares (Form 4, code D).
Dec 5, 2025: Grant or award of VOR derivative securities (Form 4, code A).
Jul 9, 2025: Grant or award of VOR shares (Form 4, code A).
Jun 5, 2025: Grant or award of CRSP derivative securities (Form 4, code A).

Other insiders filing for CRISPR Therapeutics AG (CRSP)

Sakhamuri Sivakesava, Chief Technical Officer
Silver Andrew Jacob, Chief Financial Officer
KASINGER JAMES R., General Counsel and Secretary
Kulkarni Samarth, Chief Executive Officer
Patel Naimish, Chief Medical Officer
George Simeon, Director

How to read Form 4 transaction codes